Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 11 - Anxiety

from Section 3 - Specific neuropsychiatric disorders

Related content

Powered by UNSILO

References

1. LeentjensAF, DujardinK, MarshL, et al. Anxiety rating scales in Parkinson’s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord 2011; 26: 407–15.
2. PontoneGM, WilliamsJR, AndersonKE, et al. Anxiety and self-perceived health status in Parkinson’s disease. Parkinsonism Relat Disord 2011; 17: 249–54.
3. PontoneGM, WilliamsJR, AndersonKE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson’s disease. Mov Disord 2009; 24: 1333–8.
4. LeentjensAF, DujardinK, MarshL, et al. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord 2011; 26: 484–92.
5. DissanayakaNN, SellbachA, MathesonS, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord 2010; 25: 838–45.
6. QuelhasR, CostaM.Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2009; 21: 413–19.
7. ReutherM, SpottkeEA, KlotscheJ, et al. Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 2007; 13: 108–14.
8. McKinlayA, GraceRC, Dalrymple-AlfordJC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia. Parkinsonism Relat Disord 2008; 14: 37–42.
9. LeentjensAF, DujardinK, MarshL, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2008; 23: 2015–25.
10. PalanciJ, MarshL, PontoneGM.Gaps in treatment for anxiety in Parkinson disease. Am J Geriatr Psychiatry 2011; 19: 907–8.
11. NutiA, CeravoloR, PiccinniA, et al. Psychiatric comorbidity in a population of Parkinson’s disease patients. Eur J Neurol 2004; 11: 315–20.
12. KesslerRC, ChiuWT, DemlerO, MerikangasKR, WaltersEE.Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–27.
13. LerayE, CamaraA, DrapierD, et al. Prevalence, characteristics and comorbidities of anxiety disorders in France: results from the “Mental Health in General Population” survey (MHGP). Eur Psychiatry 2011; 26: 339–45.
14. MenzaMA, Robertson-HoffmanDE, BonapaceAS.Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993; 34: 465–70.
15. GothamAM, BrownRG, MarsdenCD.Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381–9.
16. FetoniV, SoliveriP, MonzaD, TestaD, GirottiF.Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999; 66: 541–4.
17. JacobEL, GattoNM, ThompsonA, BordelonY, RitzB.Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat Disord 2010; 16: 576–81.
18. WeisskopfMG, ChenH, SchwarzschildMA, KawachiI, AscherioA.Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov Disord 2003; 18: 646–51.
19. ShibaM, BowerJH, MaraganoreDM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000; 15: 669–77.
20. GoneraEG, van’t HofM, BergerHJ, van WeelC, HorstinkMW.Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997; 12: 871–6.
21. HendersonR, KurlanR, KersunJM, ComoP.Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4: 257–64.
22. LauterbachEC, DuvoisinRC.Anxiety disorders in familial parkinsonism. Am J Psychiatry 1991; 148: 274.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
24. Wolitzky-TaylorKB, CastriottaN, LenzeEJ, StanleyMA, CraskeMG.Anxiety disorders in older adults: a comprehensive review. Depress Anxiety 2010; 27: 190–211.
25. CullyJA, StanleyMA.Assessment and treatment of anxiety in later life. In LaidlawK, KnightB, eds., The Handbook of Emotional Disorders in Later Life. New York, NY: Oxford University Press; 2008, pp. 233–56.
26. BrownRG, LandauS, HindleJV, et al. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011; 82: 803–9.
27. WetzlerS, KatzMM.Problems with the differentiation of anxiety and depression. J Psychiatr Res 1989; 23: 1–12.
28. WalshK, BennettG.Parkinson’s disease and anxiety. Postgrad Med J 2001; 77: 89–93.
29. ChrischillesEA, RubensteinLM, VoelkerMD, WallaceRB, RodnitzkyRL.Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 199–209.
30. HannaKK, Cronin-GolombA.Impact of anxiety on quality of life in Parkinson’s disease. Parkinsons Dis 2012; 2012: 640707.
31. MarinusJ, LeentjensAF, VisserM, StiggelboutAM, van HiltenJJ.Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25: 318–24.
32. KlepacN, HajnsekS, TrkuljaV.Cognitive performance in nondemented nonpsychotic Parkinson disease patients with or without a history of depression prior to the onset of motor symptoms. J Geriatr Psychiatry Neurol 2010; 23: 15–26.
33. BarlowD.Anxiety and its Disorders: the Nature and Treatment of Anxiety and Panic, 2nd edn. New York: Guilford; 2001.
34. BerriosGE, CampbellC, PolitynskaBE.Autonomic failure, depression and anxiety in Parkinson’s disease. Br J Psychiatry 1995; 166: 789–92.
35. MaricleRA, NuttJG, ValentineRJ, CarterJH.Dose–response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 1995; 45: 1757–60.
36. KummerA, CardosoF, TeixeiraAL.Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson’s disease. Arq Neuropsiquiatr 2010; 68: 495–501.
37. VazquezA, Jimenez-JimenezFJ, Garcia-RuizP, Garcia-UrraD.“Panic attacks” in Parkinson’s disease. A long-term complication of levodopa therapy. Acta Neurol Scand 1993; 87: 14–18.
38. LauterbachEC, FreemanA, VogelRL.Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cogn Behav Neurol 2003; 16: 225–33.
39. AdkinAL, FrankJS, JogMS.Fear of falling and postural control in Parkinson’s disease. Mov Disord 2003; 18: 496–502.
40. MaiaAF, PintoAS, BarbosaER, MenezesPR, MiguelEC.Obsessive-compulsive symptoms, obsessive-compulsive disorder, and related disorders in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2003; 15: 371–4.
41. AlegretM, JunqueC, ValldeoriolaF, et al. Obsessive-compulsive symptoms in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70: 394–6.
42. HollanderE, CohenL, RichardsM, et al. A pilot study of the neuropsychology of obsessive-compulsive disorder and Parkinson’s disease: basal ganglia disorders. J Neuropsychiatry Clin Neurosci 1993; 5: 104–7.
43. MullerN, PutzA, KathmannN, et al. Characteristics of obsessive-compulsive symptoms in Tourette’s syndrome, obsessive-compulsive disorder, and Parkinson’s disease. Psychiatry Res 1997; 70: 105–14.
44. IshiharaL, BrayneC.A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand 2006; 113: 211–20.
45. PontoneGM, PalanciJ, BienvenuOJ, et al. Familial aggregation of panic disturbances in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2011; 23: 417–24.
46. KesslerRC, BerglundP, DemlerO, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.
47. RajBA, CorveaMH, DagonEM.The clinical characteristics of panic disorder in the elderly: a retrospective study. J Clin Psychiatry 1993; 54: 150–5.
48. ShulmanLM, TabackRL, RabinsteinAA, WeinerWJ.Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 193–7.
49. WeintraubD, MobergPJ, DudaJE, KatzIR, SternMB.Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 2004; 52: 784–8.
50. ChengEM, TonnS, Swain-EngR, et al. Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2010; 75: 2021–7.
51. MenzaM, DobkinRD.Anxiety. In MenzaM, MarshL., eds., Psychiatric Issues in Parkinson’s Disease: a Practical Guide. London: Taylor and Francis; 2005. pp. 139–53.
52. MondoloF, JahanshahiM, GranaA, et al. Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales. Neurol Sci 2007; 28: 270–5.
53. Rodriguez-BlazquezC, Frades-PayoB, ForjazMJ, de Pedro-CuestaJ, Martinez-MartinP.Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson’s disease. Mov Disord 2009; 24: 519–25.
54. BeckAT, EpsteinN, BrownG, SteerRA.An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–7.
55. ZigmondAS, SnaithRP.The hospital anxiety and depression scale. Acta psychiatrica Scandinavica. 1983; 67: 361–70.
56. SpielbergerCD, GorsuchRL, LusheneR, VaggPR.A Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto, CA: Consultant Psychologist Press; 1983.
57. ZungWWK.A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371–9.
58. HamiltonM.The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5.
59. CummingsJL, MegaM, GrayK, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14.
60. GallagherDA, GoetzCG, StebbinsG, LeesAJ, SchragA.Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 2012; 27: 79–83.
61. GoetzCG, TilleyBC, ShaftmanSR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–70.
62. MarshL, McDonaldWM, CummingsJ, RavinaB.Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148–58.
63. MarshL, BerkA.Neuropsychiatric aspects of Parkinson’s disease: recent advances. Curr Psychiatry Rep 2003; 5: 68–76.
64. MenzaM, MarinH, KaufmanK, MarkM, LauritanoM.Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16: 315–9.
65. MenzaM, DobkinRD, MarinH, MarkMH, GaraM, BuyskeS, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886–92.
66. DobkinRD, MenzaM, BienfaitKL, et al. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2010; 22: 188–95.
67. OehlbergK, BargFK, BrownGK, et al. Attitudes regarding the etiology and treatment of depression in Parkinson’s disease: a qualitative study. J Geriatr Psychiatry Neurol 2008; 21: 123–32.
68. MohlmanJ, ReelDH, ChazinD, et al. A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease. Clin Case Stud 2010; 9: 74–90.
69. DreisingH, BeckmannJ, WermuthL, SkovlundS, BechP.Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson’s disease: a pilot study. Nord J Psychiatry 1999; 53: 217–21.
70. FeeneyF, EganS, GassonN.Treatment of depression and anxiety in Parkinson’s disease: a pilot study using group cognitive behavioural therapy. Clin Psychol 2005; 9: 31–8.
71. DobkinRD, AllenLA, MenzaM.A cognitive-behavioral treatment package for depression in Parkinson’s disease. Psychosomatics 2006; 47: 259–63.
72. DobkinRD, AllenLA, MenzaM.Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord 2007; 22: 946–52.
73. MachtM, EllgringH.Behavioral analysis of the freezing phenomenon in Parkinson’s disease: a case study. J Behav Ther Exp Psychiatry 1999; 30: 241–7.
74. VeazeyC, CookKF, StanleyM, LaiEC, KunikME.Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson’s disease. J Clin Psychol Med Settings 2009; 16: 243–53.
75. DobkinRD, MenzaM, AllenLA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry 2011; 168: 1066–74.
76. DobkinRD, MenzaM, AllenLA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011; 24: 206–14.
77. HeinrichsN, HoffmanEC, HofmannSG.Cognitive-behavioral treatment for social phobia in Parkinson’s disease: a single-case study. Cogn Behav Pract 2001; 8: 328–35.